Ethnic variations in chronic liver diseases

Digestive Diseases and Sciences

Volumn 53, Issue 5, 2008, Pages 1339-1344

  Kemmer, Nyingi ^a,b   Neff, Guy W ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Ethnicity; Liver disease; Race

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; INTERFERON; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PARACETAMOL; PREDNISONE;

ALCOHOL LIVER DISEASE; AUTOIMMUNE DISEASE; CHRONIC LIVER DISEASE; ETHNIC DIFFERENCE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CHRONIC DISEASE; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; UNITED STATES;

EID: 41949088334     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9992-0     Document Type: Review

References (85)

1. Khokhar OS, Lewis JH (2007) Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci 52:1168-1176
2. Trooskin SB, Navarro VJ, Winn RJ, Axelrod DJ, McNeal AS, Velez M, Herrine SK et al (2007) Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenterol 13:1074-1078
3. Nguyen GC, Segev DL, Thuluvath PJ (2007) Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology 45:1282-1289
4. Davila JA, El-Serag HB (2006) Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 4:104-110
5. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705-714
6. Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, Margolis HS (2006) Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131:478-484
7. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS et al (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131:470-477
8. Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350:2265-2271
9. Shiffman ML, Mihas AA, Millwala F, Sterling RK, Luketic VA, Stravitz RT, Sanyal AJ (2007) Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 102:761-766
10. Kimball P, Elswick RK, Shiffman M (2001) Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 65:510-516
11. Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, Chang KM (2003) Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 37:590-599
12. Keenan ED, Rouster SD, Shire NJ, Horn PS, Sherman KE (2004) Complexity and diversity of hepatitis C virus RNA in African Americans and whites: analysis of the envelope-coding domain. J Infect Dis 190:511-514
13. Park VM, Mason BC, Krushkal J, Li R, Riely C, Fleckenstein J (2007) Hepatitis C hypervariable region 1: association of reduced selection pressure in African Americans with treatment failure. Dig Dis Sci (in press) DOI: 10.1007/s10620-006-9726-8
14. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS (2007) Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45:80-87
15. Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Anand BS, Brau N et al (2005) Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 100:2186-2193
16. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR (2005) Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 3:604-609
17. Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD et al (2007) Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of US veterans. Dig Dis Sci 52:570-578
18. Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O et al (2006) Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int 26:1119-1125
19. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S et al (2004) The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40:484-490
20. Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, Shiffman ML (2004) A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2:469-473
21. Crosse K, Umeadi OG, Anania FA, Laurin J, Papadimitriou J, Drachenberg C, Howell CD (2004) Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2:463-468
22. Lepe R, Layden-Almer JE, Layden TJ, Cotler S (2006) Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat 13:116-120
23. Verma S, Bonacini M, Govindarajan S, Kanel G, Lindsay KL, Redeker A (2006) More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 101:1817-1823
24. Wiley TE, Brown J, Chan J (2002) Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 97:700-706
25. Pearlman BL (2006) Hepatitis C virus infection in African Americans. Clin Infect Dis 42:82-91
26. Armstrong EP, Charland SL (2004) Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin 20:671-679
27. Neal KR (2007) Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 56:1098-1104
28. Nguyen GC, Segev DL, Thuluvath PJ (2007) Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol (in press) DOI: 10.1016/j.cgh.2007.04.027
29. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL (2005) Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 42:1406-1413
30. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97-107
31. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS (1999) Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 89:14-18
32. Kramvis A, Kew MC (2007) Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 37:S9-S19
33. Gish RG, Gadano AC (2006) Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 13:787-798
34. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W et al (2003) Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 125:444-451
35. Liu CJ, Kao JH, Chen DS (2005) Therapeutic implications of hepatitis B virus genotypes. Liver Int 25:1097-1107
36. Kao JH, Chen PJ, Lai MY, Chen DS (2000) Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-559
37. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS (2000) Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33:998-1002
38. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123-129
39. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W et al (2003) Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38:619-628
40. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA (2005) Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41:372-379
41. Browning JD, Kumar KS, Saboorian MH, Thiele DL (2004) Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99:292-298
42. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395
43. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE (2002) Is NASH underdiagnosed among African Americans? Am J Gastroenterol 97:1496-1500
44. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T et al (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722-728
45. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359
46. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427-436
47. Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, De Michieli F et al (2005) Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100:2438-2446
48. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N (2005) Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 39:237-242
49. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF et al (2005) Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54:117-121
50. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA (2004) Ethnic differences in adiponectin levels. Metabolism 53:1-3
51. Ruhl CE, Everhart JE (2001) Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 74:295-301
52. Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, Diehl AM et al (2005) Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 1:6-11
53. Ratziu V, Poynard T (2006) Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44:802-805
54. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM (2006) Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44:874-880
55. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P et al (1996) Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 23:1025-1029
56. Becker U, Gronbaek M, Johansen D, Sorensen TI (2002) Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 35:868-875
57. Gronbaek M, Becker U, Johansen D, Gottschau A, Schnohr P, Hein HO, Jensen G et al (2000) Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med 133:411-419
58. Stewart SH (2002) Racial and ethnic differences in alcohol-associated aspartate aminotransferase and gamma-glutamyltransferase elevation. Arch Intern Med 162:2236-2239
59. Stinson FS, Grant BF, Dufour MC (2001) The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 25:1181-1187
60. Lorenzo A, Auguet T, Vidal F, Broch M, Olona M, Gutierrez C, Lopez-Dupla M et al (2006) Polymorphisms of alcohol-metabolizing enzymes and the risk for alcoholism and alcoholic liver disease in Caucasian Spanish women. Drug Alcohol Depend 84:195-200
61. Zintzaras E, Stefanidis I, Santos M, Vidal F (2006) Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 43:352-361
62. Lim KN, Casanova RL, Boyer TD, Bruno CJ (2001) Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 96:3390-3394
63. Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG (2002) Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 50:713-717
64. D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR (2005) An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 25:325-330
65. Acton RT, Barton JC, Snively BM, McLaren CE, Adams PC, Harris EL, Speechley MR et al (2006) Geographic and racial/ethnic differences in HFE mutation frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Ethn Dis 16:815-821
66. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW et al (2005) Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352:1769-1778
67. de Serres FJ (2002) Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 122:1818-1829
68. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP (2007) Population-based surveillance for acute liver failure. Am J Gastroenterol 102:1-5
69. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P (2004) Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 10:1018-1023
70. Kronenberg F, Cushman LF, Wade CM, Kalmuss D, Chao MT (2006) Race/ethnicity and women's use of complementary and alternative medicine in the United States: results of a national survey. Am J Public Health 96:1236-1242
71. Verma S, Thuluvath PJ (2007) Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol 5:408-416
72. Schiano TD (2003) Hepatotoxicity and complementary and alternative medicines. Clin Liver Dis 7:453-473
73. Neff GW, O'Brien C, Montalbano M, DeManno A, Kahn S, Safdar K, Nishida S et al (2004) Consumption of dietary supplements in a liver transplant population. Liver Transpl 10:881-885
74. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM et al (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947-954
75. Heijne WH, Stierum RH, Leeman WR, van Ommen B (2005) The introduction of toxicogenomics; potential new markers of hepatotoxicity. Cancer Biomark 1:41-57
76. McGlynn KA, Tarone RE, El-Serag HB (2006) A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomark Prev 15:1198-1203
77. Kemmer N, Neff G, Secic M, Zacharias V, Kaiser T, Buell J (2007) Ethnic differences in hepatocellular carcinoma: implications for liver transplantation. Dig Dis Sci (in press) DOI: 10.1007/s10620-007-9872-7
78. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB (2002) Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 36:410-417
79. Harrison LE, Reichman T, Koneru B, Fisher A, Wilson D, Dela Torre A, Samanta A et al (2004) Racial discrepancies in the outcome of patients with hepatocellular carcinoma. Arch Surg 139:992-996
80. Reid AE, Resnick M, Chang Y, Buerstatte N, Weissman JS (2004) Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl 10:834-841
81. Nair S, Eustace J, Thuluvath PJ (2002) Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 359:287-293
82. Lindholm A, Welsh M, Alton C, Kahan BD (1992) Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 52:359-371
83. Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, Benet LZ et al (2001) The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24-31
84. Fredericks S, Holt DW, MacPhee IA (2003) The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenomics 3:291-301
85. Burckart GJ, Liu XI (2006) Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 28:23-30